Brokerages Set ImmunoGen, Inc. (NASDAQ:IMGN) Target Price at $14.30

Shares of ImmunoGen, Inc. (NASDAQ:IMGN) have been given an average recommendation of “Hold” by the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $14.30.

Shares of ImmunoGen (NASDAQ:IMGN) traded down 5.08% on Monday, hitting $12.88. The stock had a trading volume of 343,486 shares. ImmunoGen has a 12 month low of $5.85 and a 12 month high of $19.43. The stock’s market cap is $1.12 billion. The firm has a 50 day moving average of $13.11 and a 200 day moving average of $13.54.

ImmunoGen (NASDAQ:IMGN) last issued its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.04. The business earned $14.90 million during the quarter, compared to the consensus estimate of $15.84 million. During the same period in the prior year, the company posted ($0.26) EPS. The company’s revenue was up 12.9% compared to the same quarter last year. On average, equities analysts forecast that ImmunoGen will post ($1.44) earnings per share for the current fiscal year.

In related news, CEO Daniel M. Junius sold 5,335 shares of the stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $12.01, for a total transaction of $64,073.35. Following the transaction, the chief executive officer now directly owns 154,115 shares in the company, valued at $1,850,921.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Charles Q. Morris sold 5,170 shares of the stock in a transaction dated Friday, November 27th. The stock was sold at an average price of $14.00, for a total value of $72,380.00. Following the transaction, the vice president now owns 27,090 shares in the company, valued at $379,260. The disclosure for this sale can be found here.

IMGN has been the subject of a number of research reports. Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Monday, October 19th. Cantor Fitzgerald reissued a “hold” rating and issued a $19.00 target price (down previously from $21.00) on shares of ImmunoGen in a report on Monday, September 21st. Morgan Stanley lowered ImmunoGen from an “equal weight” rating to an “underweight” rating and dropped their target price for the company from $10.00 to $9.00 in a report on Monday, September 21st. Oppenheimer reissued a “buy” rating on shares of ImmunoGen in a report on Monday, September 21st. Finally, Canaccord Genuity reissued a “buy” rating and issued a $20.00 target price on shares of ImmunoGen in a report on Monday, September 21st.

12 Month Chart for NASDAQ:IMGN

ImmunoGen, Inc. is a biotechnology company. The Company develops targeted anticancer therapeutics. The Company has three wholly-owned product candidates in clinical testing, with seven additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. The Company’s clinical-stage product candidates, include IMGN289, IMGN853 and IMGN529. IMGN289 compound is a treatment for many cases of head and neck cancers. IMGN853 compound is a potential treatment for epithelial ovarian cancer, endometrial cancer and other cancers. IMGN529 compound is used for the treatment of NHL (NASDAQ:IMGN). The Company’s IMGN529 ADC is a new treatment for cancers that express CD37, such as NHL and chronic lymphocytic leukemia.

 

Latest News

Oracle Buying Textura at a Price of $663 Million
Oracle Buying Textura at a Price of $663 Million
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
Verizon Working With Authorities On Sabotage Incidents
Verizon Working With Authorities On Sabotage Incidents
UPS Profit Increases During First Quarter by 10%
UPS Profit Increases During First Quarter by 10%
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Boeing Profit Drops on Lag in Commercial Deliveries
Boeing Profit Drops on Lag in Commercial Deliveries


Leave a Reply

 
© 2006-2017 The Vista Voice. Subscribe